ILLUMINA INC.

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock



Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	2,609,000,000		3,561,000,000		2,713,000,000	
Common stock capital		2,000,000		2,000,000		2,000,000
Fixed assets	7,502,000,000		8,691,000,000		12,504,000,000	
Equity capital of a company		5,745,000,000		6,599,000,000		10,740,000,000
Cash and cash equivalents	1,048,000,000		2,011,000,000		1,232,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		1,570,000,000		2,773,000,000		1,093,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		2,796,000,000		2,880,000,000		3,384,000,000
Different income		-		-		-
Other liabilities		620,000,000		649,000,000		915,000,000
Total assets	10,111,000,000	10,111,000,000	12,252,000,000	12,252,000,000	15,217,000,000	15,217,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	12,010	11,500	9,800
Equity ratio	56.82%	53.86%	70.58%
Debt-equity ratio	76.00%	85.66%	41.69%

Others

	2023	2022	2021
Tax Expense Rate	-3.94%	-1.57%	13.80%

ILLUMINA INC.

ISIN:	US4523271090	WKN:	452327109	Asset Class:	Stock

Income statement

	2023	2022	2021
Turnover	4,504,000,000	4,584,000,000	4,526,000,000
Net income	-1,161,000,000	-4,404,000,000	762,000,000
EBIT	-1,013,124,600	-3,986,986,700	871,951,500
Operating income before taxes	-1,117,000,000	-4,336,000,000	884,000,000
Cash Flow	477,000,000	392,000,000	545,000,000
Net interest income	-19,000,000	-15,000,000	-61,000,000
Research and development expenses	1,330,000,000	1,321,000,000	1,185,000,000
Income taxes	44,000,000	68,000,000	122,000,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	346,032	367,796	426,137

Board of Directors

Members of Management Board

Stephen MacMillan	Chairman of Board of Directors
Frances Arnold	Member of Board of Directors
Gary Guthart	Member of Board of Directors
Robert Epstein	Member of Board of Directors
Scott Gottlieb	Member of Board of Directors
Anna Richo	Member of Board of Directors
Caroline Dorsa	Member of Board of Directors
Philip Schiller	Member of Board of Directors
Scott Ullem	Member of Board of Directors
Susan Siegel	Member of Board of Directors
Jacob Thaysen	Chairman of Managing Board
Carissa Rollins	Member of Executive Committee
Joydeep Goswami	Member of Executive Committee
Kathryne Reeves	Member of Executive Committee
Steve Barnard	Member of Executive Committee